Long-term Results of Single-Agent Thalidomide as Initial Therapy for Asymptomatic (Smoldering or Indolent) Myeloma

We report the long-term follow-up results of a phase II trial of thalidomide for early stage multiple myeloma (MM). Patients were eligible if they had smoldering multiple myeloma (SMM) or indolent MM without need for immediate therapy. Thalidomide was initiated at a dose of 200 mg/day and adjusted a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Detweiler-Short, Kristen, Hayman, Suzanne, Gertz, Morie A., Lacy, Martha Q., Dispenzieri, Angela, Kumar, Shaji, Zeldenrust, Steven R., Russell, Stephen J., Lust, John A., Kyle, Robert A., Greipp, Philip R., Witzig, Thomas E., Rajkumar, S. Vincent
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3022372/
https://ncbi.nlm.nih.gov/pubmed/20730790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.21821
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados